Company & Sponsor Intelligence
All India Institute of Medical Sciences, Bhubaneswar
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting1
Completed3
Countries1
Therapeutic footprint
autismdepressionepilepsyout_of_scope
Indexed studies
NCT05868720EFFECT OF RISPERIDONE vs ARIPIPRAZOLE ON OXIDATIVE STRESS IN PATIENTS WITH AUTISM SPECTRUM DISORDER: A RANDOMIZED CONTROLLED TRIAL
autism · NA
autism · NA
NCT07131813Evaluation of Efficacy and Safety of add-on Tofacitinib in Patients With Oral Lichen Planus
out_of_scope · IndiaPHASE4
out_of_scope · IndiaPHASE4
NCT04975100Evaluation of Efficacy and Safety of add-on Sarcosine in Patients With Major Depressive Disorder
depression · IndiaPHASE4
depression · IndiaPHASE4
NCT06260904Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus
out_of_scope · IndiaPHASE4
out_of_scope · IndiaPHASE4
NCT03590197Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy
epilepsy · IndiaPHASE4
epilepsy · IndiaPHASE4
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →